引用本文:[点击复制]
[点击复制]
【打印本页】 【在线阅读全文】【下载PDF全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 21次   下载 4 本文二维码信息
码上扫一扫!
糖尿病患者起始胰岛素治疗方案的选择及安全性评价
高琳,徐晶,苏振丽,张杨
0
(陕西省宝鸡市中心医院老年病内分泌科)
摘要:
【摘要】目的 探讨口服二甲双胍控糖效果不佳糖尿病患者起始胰岛素治疗方案的选择及安全性。方法 选取口服二甲双胍控糖效果不佳的2型糖尿病患者126例随机分为3组,在二甲双胍治疗基础上,分别联用西格列汀、起始剂量10 U/d胰岛素、起始剂量15 U/d胰岛素分别作为A组、B组、C组,治疗期间均根据血糖控制情况调整用药剂量,达到并维持空腹血糖≤56 mmol/L。记录3组血糖达标率、达标时间、低血糖反应;计算治疗前后体重指数(BMI)、体重差值,统计三组治疗前后空腹血糖(FPG)、餐后2h血糖(2hPG)、糖化血红蛋(HbA1c)、胰岛素抵抗指数(HOMAIR)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDLC)。结果〓本研究中A组5例脱落,B组7例脱落,C组8例脱落。3组患者血糖达标率、低血糖反应发生率比较差异无统计学意义(P>005);C组血糖达标时间短于A组、B组(P<005),但A组、B组比较差异无统计学意义(P>005)。3组治疗后FPG、2hPG、HbA1c、HOMAIR均下降,FINS上升,同组治疗前后差异有统计学意义(P<005),但3组组间比较差异无统计学意义(P>005)。A组治疗前后BMI、体重差值低于B组、C组,差异有统计学意义(P<005),但B组、C组比较差异无统计学意义(P>005)。结论〓口服二甲双胍控糖效果不佳2型糖尿病患者联合西格列汀、甘精胰岛素均可获得理想的降糖效果,且加大基础甘精胰岛素方案起始用药剂量可缩短血糖达标时间,但西格列汀在控制体重上更具优势。
关键词:  2型糖尿病  二甲双胍  西格列汀  甘精胰岛素
DOI:
基金项目:国家自然科学基金青年科学基金(8130159)
The choice of initial insulin treatment plan for patients with diabetes mellitus inadequately controlled with oral antidiabetic drugs
GAO Lin,XU Jing,SU Zhenli,ZHANG Yang
(Department of Endocrinology, Baoji Central Hospital)
Abstract:
【Abstract】Objective To investigate the initial insulin treatment plan for patients with diabetes mellitus inadequately controlled with oral antidiabetic drugs and analyze its safety. Methods 126 patients with diabetes mellitus inadequately controlled with metformin were randomized into group A, group B and group C. On the basis of treatment with metformin, group A were treated with sitagliptin, group B with starting dose 10 U/d of insulin and group C with 15 U/d of insulin. According to the blood glucose control during treatment, the dose was adjusted to maintain the fasting blood glucose ≤ 56 mmol/L. The control rates of blood glucose, standard time and incidence of hypoglycemia in the three groups were recorded. The body mass index (BMI) and body weight difference were calculated. The fasting plasma glucose (FPG), postprandial 2h plasma glucose (2hPG), glycosylated hemoglobin (HbA1c), insulin resistance index (HOMAIR), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) in the three groups were statistically analyzed before and after treatment. Results There were 5 cases in group A, 7 cases in group B and 8 cases in group C lost to follow up. There was no significant difference in the control rate of blood glucose and incidence of hypoglycemia among the three groups (P>0.05). The standard time of group C was shorter than that of group A and group B (P<0.05) but there was no significant difference between group A and group B (P>0.05). After treatment, FPG, 2hPG, HbA1c and HOMAIR decreased in the three group while FINS increased (P<0.05) but there was no significant difference between groups (P>0.05). BMI and body weight difference of group A were lower than those of group B and group C (P<0.05) but there was no significant difference between group B and group C (P>0.05). Conclusion The hypoglycemic effects of sitagliptin and insulin glargine are good in patients with diabetes mellitus inadequately controlled with metformin. High starting dose of insulin glargine can shorten the standard time of blood glucose but sitagliptin has more advantages in controlling weight.
Key words:  Type 2 diabetes mellitus  Metformin  Sitagliptin  Insulin glargine  Dose

用微信扫一扫

用微信扫一扫